A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

NCT02651688 | Completed Phase 2 Results

• 1 other identifier: ZA-205
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 5

Brief Summary

The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism \[confirmed morning testosterone (T) ≤300 ng/dL\] following a 6 month diet and 15 month exercise program.

Conditions

Acquired Hypogonadotropic Hypogonadism; Obesity

Outcome Measures

Primary Outcomes (20)

• Change From Baseline in Lean Body Mass (LBM) at Week 48

  LBM was assessed using dual-energy X-ray absorptiometry (DXA). A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Body Strength (Chest Press Weight) at Week 48

  Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Body Strength (Leg Press Weight) at Week 48

  Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter LH measured in milli-International Units per milliliter (mIU/mL). A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Testosterone (T) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter T. A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter DHT. A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Estradiol (E2) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter E2. A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48

  The T:E2 ratio was calculated as the value of T/value of E2 using the same units. A positive change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48

  The DHT:T ratio was calculated as the value of DHT/value of T using the same units. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter HbA1c. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Glucose Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter Glucose. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter CRP. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter IL-6. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter TNF-α . A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Leptin Level at Week 48

  A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter leptin. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48

  The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) × fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48

  Quantose-IR is a laboratory-developed test that assesses insulin resistance. Quantose-IR score is based on a linear regression algorithm utilizing the quantitative measures (natural log transformed) of alpha-hydroxybutyrate, oleate, linoleoylglycerophosphocholine and insulin and was designed to estimate the natural log of insulin-induced glucose infusion rate normalized by whole body mass. The algorithm score is converted to the Quantose-IR score within a range of 1-120 by an arithmetic calculation where higher scores denote greater insulin resistance. A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Body Mass Index (BMI) at Week 48

  BMI is calculated as weight (kg)/height(cm\^2). A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Waist Circumference at Week 48

  A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

• Change From Baseline in Weight at Week 48

  A negative change from Baseline indicates improvement.

  Baseline (Day 0) to Week 48

Study Arms (3)

Enclomiphene 12.5 mg

EXPERIMENTAL

Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.

Drug: Enclomiphene

Enclomiphene 25 mg

EXPERIMENTAL

Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.

Drug: Enclomiphene

Placebo

PLACEBO COMPARATOR

One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.

Drug: Placebo

Interventions

Placebo DRUG

One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Placebo

Enclomiphene DRUG

Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Enclomiphene 12.5 mg; Enclomiphene 25 mg

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Overweight (Body Mass Index (BMI) 30 to 42 (kg/m\^2) inclusive) males age 18 to 60 inclusive.
• Waist circumference ≥ 40 inches (101.6 cm).
• Previously or concurrently diagnosed as having secondary hypogonadism.
• Must have 2 morning testosterone assessments at Visit 1, collected before 10 AM, 2-4 days apart, and both of which must be ≤ 300 (ng/dL).
• Luteinizing hormone (LH) \>1.4 and \< 9.4 milli International units per milliliter (mIU/mL) (at Visit 1 only).
• Glycated hemoglobin A1c (HbA1c) ≤7.5.
• Stable weight for last 3 months (+/- 10 pounds).
• Participant lives or works within 10 miles of the gym that will be used for the study.
• Must be fit enough to participate in the fitness program.
• Ability to complete the study in compliance with the protocol requirements.
• Ability to understand and provide written informed consent.

You may not qualify if:

• Any use of testosterone products (injectable, pelleted, transdermal or sublingual) in the 6 months prior to the study or any prior use of testosterone products for 12 months or longer at any time.
• Use of testosterone, Clomid, 5α-reductase inhibitors, human chorionic gonadotropin (hCG), androgen, estrogen, anabolic steroid, dehydroepiandrosterone (DHEA), or herbal hormone products during the study.
• Use of Clomid in the past year.
• Known hypersensitivity to Clomid.
• Allergy to soy, peanuts or latex.
• Chronic use of glucocorticoids (chronic use of inhaled or topical glucocorticoids is acceptable).
• History of drug abuse or chronic narcotic use including methadone.
• A recent history of alcoholism or illegal substance or steroid abuse (\<2 years) or presence of moderate alcohol use (\>21 drinks per week).
• Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
• A hematocrit \>54%.
• Presence or known history of hyperprolactinemia with or without a tumor (prolactin \>20 ng/mL).
• Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a prostate specific antigen (PSA)\>3.6.
• Current or history of breast cancer.
• Uncontrolled hypertension based on the Investigator's assessment at screening.
• History of bulimia nervosa or binge eating.

Sponsors & Collaborators

• Repros Therapeutics Inc.: lead

Study Sites (5)

Unknown Facility

Albany, New York, 12208, United States

Location

Unknown Facility

Garden City, New York, 11530, United States

Location

Unknown Facility

Providence, Rhode Island, 02903, United States

Location

Unknown Facility

Riverton, Utah, 84065, United States

Location

Unknown Facility

Norfolk, Virginia, 23507, United States

Location

MeSH Terms

Conditions

Obesity

Interventions

Enclomiphene

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Clomiphene; Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: Therapeutic Area, Head
• Organization: Allergan

clinicaltrials@allergan.com

714-246-4500

Study Officials

• Anna Chan

  Allergan

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2016
• First Posted: January 11, 2016
• Study Start: January 11, 2016
• Primary Completion: May 2, 2017
• Study Completion: May 2, 2017
• Last Updated: June 27, 2019
• Results First Posted: June 14, 2019

Record last verified: 2019-06

Locations

US (5)